ASC 730-10 requires companies reporting under US GAAP to charge research and development costs to expense in the period they are incurred, with one narrow exception for equipment and facilities that have an alternative future use. The rule exists because the link between R&D spending and any future payoff is too speculative to support putting those costs on the balance sheet. It also removes management’s discretion over the timing of R&D recognition, which makes financial statements far more comparable across companies.
What Counts as Research and Development
The FASB codification defines research as a planned search or critical investigation aimed at discovering new knowledge, with the hope that the knowledge will prove useful in developing or significantly improving a product or process. Development is the next step: translating research findings or other knowledge into a plan or design for a new or substantially improved product or process. That includes formulating concepts, designing and testing alternatives, building prototypes, and running pilot plants.
The codification lists activities that fall inside the definition:
- Laboratory research aimed at discovering new knowledge
- Conceptual formulation and design of possible product or process alternatives
- Testing and evaluation of product or process alternatives
- Design, construction, and testing of preproduction prototypes and models
- Design and operation of a pilot plant that is not economically feasible for commercial production
- Engineering activity required to advance a product design to the point it meets functional and economic requirements and is ready for manufacture
Several categories of work are specifically outside the definition. Quality control during commercial production, troubleshooting breakdowns on the production line, routine or seasonal changes to existing products, market research and market testing, and legal work on patent applications or litigation are not R&D. Neither is the development of processes used strictly in selling or administrative functions, even when software is involved.
Getting this classification right matters. Costs falling outside ASC 730-10 are not subject to the immediate expensing requirement and may be capitalized or treated some other way depending on the applicable guidance. Misclassifying an activity as R&D, or missing an activity that qualifies, affects both the income statement and the balance sheet.
Which Costs Get Expensed
Once an activity qualifies as R&D, ASC 730-10-25-1 is blunt: all R&D costs shall be charged to expense when incurred.1FASB. Research and Development (Topic 730) There is no probability threshold that triggers capitalization, no milestone-based recognition, and no management election to defer costs. A scientist’s salary is expensed in the month the work is performed. Materials consumed in a failed experiment hit the income statement in the quarter they were used. If a company spends $500,000 on qualifying R&D salaries and $150,000 on materials in a quarter, the full $650,000 flows through as R&D expense.
The cost buckets that need to be captured include:
- Materials consumed in research, such as chemicals and prototype components
- Salaries, wages, and related benefits of employees directly engaged in R&D work
- Fees paid to consultants, contractors, or other third parties performing R&D on the company’s behalf
- A reasonable allocation of overhead, such as rent and utilities for an R&D facility, charged in the same period as the direct costs it supports
- Equipment and facilities acquired solely for a particular R&D project with no other economic value, expensed in full at acquisition
The decision to expense is final. Costs recognized as R&D expense in one period cannot be retroactively capitalized if the project later succeeds. Recognition tracks the period the cost is incurred, not when a patent is filed, a prototype works, or a product launches.
This approach departs from the matching principle that normally aligns costs with the revenue they help produce. The FASB chose a conservative path because most R&D projects fail, and even successful ones may not generate identifiable revenue for years. Capitalizing those costs would put speculative assets on the balance sheet and give managers room to smooth earnings by choosing which projects to capitalize and when.
The Alternative-Future-Use Exception
Not every asset used in R&D gets expensed immediately. Under ASC 730-10-25-2(a), materials, equipment, and facilities that have an alternative future use are capitalized when acquired and depreciated normally. Only the depreciation allocated to R&D periods is charged to R&D expense.1FASB. Research and Development (Topic 730)
A general-purpose laboratory building, a computer server that will serve multiple departments, or testing equipment usable across several projects all pass the test. Those assets go on the balance sheet and are depreciated over their useful lives. A custom testing rig built for a single experimental compound, with no resale value and no use in any other project, fails the test and is written off entirely when purchased.
The determination happens at the time of acquisition, not retroactively. If a company buys a machine believing it will serve only one project and later finds a second use for it, the cost has already been expensed. Judgment matters here, and inconsistency between similar purchases is exactly the kind of thing auditors push back on.
Internal-Use Software Is Handled Separately
Software developed for a company’s own use does not follow ASC 730-10. It follows ASC 350-40, which allows capitalization of certain costs once the project meets specific criteria and requires expensing before and after that window. If you are accounting for a project to build internal-use software, ASC 730-10 is the wrong starting point.
R&D costs for computer software that will be sold, leased, or otherwise marketed do fall within ASC 730-10’s disclosure requirements, and are called out expressly in the disclosure rule.2Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive
Acquired In-Process R&D in a Business Combination
When a company acquires another business under ASC 805, incomplete R&D projects at the target receive different treatment than internally generated R&D. The acquirer capitalizes the in-process research and development at fair value as a separate intangible asset on the acquisition date, typically using a discounted cash flow method to estimate the future revenue the project could generate.
Acquired IPR&D is classified as an indefinite-lived intangible and is not amortized while the project remains in progress. It must be tested for impairment at least annually. When the project reaches completion, the asset is reclassified as a definite-lived intangible, such as a patent or developed technology, and amortized over its remaining useful life. If the project is abandoned, the entire capitalized balance is written off as an impairment loss.
The logic behind the exception: in a business combination, the acquirer paid real consideration for these projects, and the purchase price already reflects the market’s assessment of their risk-adjusted value. Expensing them immediately would distort the economics of the transaction.
R&D Performed for or by Someone Else
Companies frequently pay third parties to perform R&D or receive funding from others to conduct research. The accounting depends on who bears the risk of the outcome.
When a company hires a contractor to perform R&D, the company expenses the payments as R&D costs in the periods the services are provided. Nonrefundable advance payments for future R&D services are deferred and recognized as R&D expense as the work is performed. If it becomes probable that the services will not be rendered, any remaining prepayment is expensed immediately.
The contractor performing the work does not report R&D expense. It treats its costs as cost of revenue and the payments received as service revenue, because the economic risk of the R&D outcome sits with the party paying for it.
ASC 730-20 covers more complex funding arrangements where an entity obtains money from outside parties to conduct R&D while potentially retaining rights to the results. The question is whether a genuine transfer of financial risk has occurred. If repayment depends solely on whether the R&D produces future economic benefits, the arrangement is treated as a contract to perform R&D services, and the funding is recognized as revenue. If the entity has an obligation to repay regardless of outcome, the funding is a liability.
Required Disclosures
ASC 730-10-50-1 requires companies to disclose the total R&D costs charged to expense in each period for which an income statement is presented, including R&D costs incurred for computer software to be sold, leased, or otherwise marketed.2Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive
The disclosure typically appears in the notes to the financial statements, though some companies present R&D as a separate line item on the income statement itself. The accounting policy note should describe how the company treats R&D costs, particularly the criteria used to decide whether equipment and facilities have alternative future uses.
How ASC 730-10 Differs From IFRS
Companies reporting under International Financial Reporting Standards follow IAS 38, which takes a different approach. IFRS agrees that research costs must be expensed as incurred, but it requires capitalization of development costs once a project meets six specific criteria: technical feasibility has been demonstrated, management intends to complete the project and use or sell the resulting asset, the entity has the ability to use or sell the asset, the asset will generate probable future economic benefits, adequate technical and financial resources are available to complete the project, and the entity can reliably measure the development costs.
Two companies working on identical projects can report very different results depending on the framework. The IFRS approach produces higher reported assets and potentially smoother earnings, since capitalized development costs are amortized over the asset’s useful life rather than hitting the income statement at once. The US GAAP approach produces lower reported assets and more volatile earnings during heavy R&D periods, but avoids the judgment calls and manipulation risk that come with deciding when the six IFRS criteria have been met.
For multinational companies preparing dual reports, reconciling these two frameworks is a recurring source of complexity. Parent companies reporting under IFRS with US subsidiaries, or vice versa, need parallel tracking of development costs to produce accurate statements under each standard.
What ASC 730-10 Does Not Cover
The standard does not apply to every activity that looks like R&D. It explicitly excludes R&D performed under contract for another party, which falls under general contract accounting. It also excludes activities unique to extractive industries, such as prospecting, exploration, and drilling, though extractive companies still apply ASC 730-10 to R&D activities comparable to those of other entities, such as developing improved extraction techniques.
Routine or periodic alterations to existing products, production lines, or manufacturing processes are outside the scope even when they represent improvements. Market research and market testing are outside the scope because they relate to the selling function. Development or improvement of processes used only in selling or administrative activities is outside the scope, including software costs tied to those activities.